PLEGRIDY 3-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients

By: via Benzinga
Today Biogen (NASDAQ: BIIB) announced new data from the ATTAIN study which demonstrate the long-term safety and efficacy of PLEGRIDY® ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.